Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript [Seeking Alpha]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Seeking Alpha
Company Participants Louis Tamayo - CFO & Principal Accounting Officer Eric Adler - Chief Medical Officer & Head of Research Victoria Parikh Conference Call Participants Geulah Livshits - Chardan Capital Markets, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Mariam Waggeh - JPMorgan Chase & Co, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Hongye Wei - Guggenheim Securities, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Operator Good afternoon, and welcome to the fireside chat titled: A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy, hosted by Lexeo Therapeutics. As a reminder, this call is being recorded today, Tuesday, December 9. I would now like to turn the call over to Louis Tamayo, Chief Fin
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryGlobeNewswire
- H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 2/6/26 - Form 4
- 2/6/26 - Form 4
- 2/6/26 - Form 4
- LXEO's page on the SEC website